# US 2025/0205262 A1 · Sphingolipid-loaded nanobiologics for immune regulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205262 A1
- Document ID: US20250205262A1
- Status: Published application
- Kind: A1
- Application number: 18/850,960
- Filed: 2023-03-30
- Published: 2025-06-26
- Earliest claimed: 2022-03-31
- Assignees: Icahn School of Medicine at Mount Sinai; Stichting Radboud universitair medisch centrum
- Applicants: Icahn School of Medicine At Mount Sinai; Stichting Radboud Universitair Medisch Centrum
- Inventors: Abraham J. Teunissen; Willem J. Mulder; Raphaël Duivenvoorden; Zahi A. Fayad
- Web page: https://patentgrep.com/patent/US20250205262A1

## CPC

- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6917: {the form being a lipoprotein vesicle, e.g. HDL or LDL proteins}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are sphingolipid-loaded nanobiologics comprising: an apolipoprotein A-1 (apoA-1) or a peptide mimetic of apoA-1; a sphingolipid; and cholesterol, and uses thereof e.g., a method of innate immune regulation including stimulating a trained immunity response in a subject, and a method of treatment of cancer, comprising administering a nanobiologic composition.

## Claims

### Claim 1

A nanobiologic composition comprising:
(a) a apolipoprotein A-I (apoA-I) or a peptide mimetic of apoA-I;
(b) a sphingolipid; and
(c) cholesterol;
wherein the composition is a nanoparticle having a diameter between about 8 nm and about 150 nm.

### Claim 2 (depends on 1)

The nanobiologic composition of claim 1, wherein the sphingolipid is selected from the group consisting of a ceramide, sphingomyelin, dihydroceramide, glucosylceramide, sphingosine, sphingosine-1-phosphate, galactosylceramide, ceramide-1-phosphate, lactosylceramide, and mixtures thereof.

### Claim 3 (depends on 2)

The nanobiologic composition of claim 2, wherein the sphingolipid is selected from the group consisting of a glucosylceramide, galactosylceramide, or lactosylceramide.

### Claim 4 (depends on 3)

The nanobiologic composition of claim 3, wherein the sphingolipid is a glucosylceramide or a galactosylceramide.

### Claim 5 (depends on 4)

The nanobiologic composition of claim 4, wherein the sphingolipid is a glucosylceramide.

### Claim 6 (depends on 4)

The nanobiologic composition of claim 4, wherein the sphingolipid is a galactosylceramide.

### Claim 7 (depends on 1)

The nanobiologic composition of claim 1, wherein the sphingolipid is of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a saturated aliphatic chain or an unsaturated aliphatic chain;
R2 is H, R4, or C(O)R4;
R3 is H, a sugar, P(O)(OH)2, or P(O)(OH)O(CH2)nR5 where n=1-10;
R4 is a saturated aliphatic chain or an unsaturated aliphatic chain; and
R5 is H, NH2, N(CH3)3+, OH, or a sugar.

### Claim 8 (depends on 7)

The nanobiologic composition of claim 7, wherein
R1 is a unsaturated C14-24 aliphatic chain.
R2 is C(O)R4;
R3 is
and
R4 is a C11-30 unsaturated aliphatic chain or a C11-30 saturated aliphatic chain.

### Claim 9 (depends on 8)

The nanobiologic composition of claim 8, wherein R1 is a unsaturated C15-17 aliphatic chain.

### Claim 10 (depends on 9)

The nanobiologic composition of claim 9, wherein
R1 is a unsaturated C15-17 aliphatic chain;
R2 is C(O)R4;
R3 is
and
R4 is a C11-30 unsaturated aliphatic chain.

### Claim 11 (depends on 7, 8, 9, 10)

The nanobiologic composition of any one of claims 7-10, wherein R1 is a Cis alkenyl.

### Claim 12 (depends on 7, 8, 9, 10, 11)

The nanobiologic composition of any one of claims 7-11, wherein R4 is a C14-24 unsaturated aliphatic chain or a C14-24 saturated aliphatic chain.

### Claim 13 (depends on 12)

The nanobiologic composition of claim 12, wherein R4 is a C17 alkenyl or a C23 alkenyl.

### Claim 14 (depends on 7, 8, 9, 10, 11, 12, 13)

The nanobiologic composition of any one of claims 7-13, wherein R3 is

### Claim 15 (depends on 1, 2)

The nanobiologic composition of claim 1 or 2, wherein the sphingolipid is selected from the group consisting of:

### Claim 16 (depends on 15)

The nanobiologic composition of claim 15, wherein the sphingolipid is selected from the group consisting of:

### Claim 17 (depends on 15)

The nanobiologic composition of claim 15, wherein the sphingolipid is selected from the group consisting of:

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The nanobiologic composition of any one of claims 1-17, comprising a phospholipid.

### Claim 19 (depends on 18)

The nanobiologic composition of claim 18, wherein the phospholipid is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and mixtures thereof.

### Claim 20 (depends on 19)

The nanobiologic composition of claim 19, wherein the phospholipid is DMPC.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The nanobiologic composition of any one of claims 1-17, comprising a phospholipid and a lysophospholipid.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The nanobiologic composition of any one of claims 1-21, wherein the phospholipid is 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).

### Claim 23 (depends on 21)

The nanobiologic composition of claim 21, wherein the lysophospholipid is selected from the group consisting of 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (MHPC), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (PHPC), 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (SHPC), and mixtures thereof.

### Claim 24 (depends on 21)

The nanobiologic composition of claim 21, wherein the phospholipid is 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and the lysophospholipid is 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (PHPC).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The nanobiologic composition of any one of claims 1-24, wherein the nanobiologic composition comprises human apolipoprotein A-I (apoA-I).

### Claim 26 (depends on 18, 19, 20, 21, 22, 23, 24, 25)

The nanobiologic composition of any one of claims 18-25, wherein the sphingolipid is present in about 1-50 mol % of the total lipid composition.

### Claim 27 (depends on 26)

The nanobiologic composition of claim 26, wherein the sphingolipid is present in about 10-25 mol % of the total lipid composition.

### Claim 28 (depends on 27)

The nanobiologic composition of claim 27, wherein the sphingolipid is present in about 20 mol % of the total lipid composition.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The nanobiologic composition of any one of claims 1-28, wherein the cholesterol is present in about 1-30 mol % relative to the phospholipid.

### Claim 30 (depends on 29)

The nanobiologic composition of claim 29, wherein the cholesterol is present in about 5-25 mol % relative to the phospholipid.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The nanobiologic composition of any one of claims 1-30, wherein the phospholipid, sphingolipid, and cholesterol are present in a molar ratio of about 1:0.05-0.25:0.05-0.25.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The nanobiologic composition of any one of claims 1-31, wherein the nanobiologic composition has a PDI of about 0.1 to about 0.3.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The nanobiologic composition of any one of claims 1-32, wherein the nanoparticle has a diameter between about 20 nm to about 100 nm.

### Claim 34 (depends on 33)

The nanobiologic composition of claim 33, wherein the nanoparticle has a diameter between about 25 nm to about 60 nm.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The nanobiologic composition of any one of claims 1-34, wherein the nanoparticle is spherical.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The nanobiologic composition of any one of claims 1-35, wherein the nanoparticle is discoidal.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The nanobiologic composition of any one of claims 1-36, wherein the nanobiologic composition is suitable for intravenous or intra-arterial administration.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method for treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of a nanobiologic composition of any one of claims 1-37.

### Claim 39 (depends on 38)

The method of claim 38, wherein the cancer is selected from the group consisting of bladder cancer, cancer of the blood vessels, bone cancer, brain cancer, breast cancer, cervical cancer, chest cancer, colon cancer, endometrial cancer, esophageal cancer, eye cancer, head cancer, kidney cancer, liver cancer, cancer of the lymph nodes, lung cancer, mouth cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, colorectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, urothelial cancers, and uterine cancer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, melanoma, colorectal cancer, lung cancer, pancreatic cancer, and glioblastoma.

### Claim 41 (depends on 38, 39, 40)

The method of any one of claims 38-40, wherein the nanobiologic composition is administered intravenously or intra-arterially.

### Claim 42 (depends on 38, 39, 40, 41)

The method of any one of claims 38-41, wherein the subject is a human.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method of stimulating a trained immunity response in a subject comprising administering
(i) a nanobiologic composition of any one of claims 1-37; and
(ii) a trained immune promoter.

### Claim 44 (depends on 43)

The method of claim 43, wherein the trained immunity promoter is a Dectin-1 receptor agonist, a NOD-2 agonist, or a combination thereof.

### Claim 45 (depends on 43)

The method of claim 43, wherein the nanobiologic composition comprises the trained immunity promoter.

### Claim 46 (depends on 43)

The method of claim 43, wherein the nanobiologic composition and the trained immunity promoter are administered in separate compositions.

### Claim 47 (depends on 46)

The method of claim 46, wherein the nanobiologic composition and trained immunity promoter are administered within up to 1, 2, 3, 4, 5, 6, or 7 days of each other.

### Claim 48 (depends on 46, 47)

The method of claim 46 or 47, wherein the routes of administration are the same.

### Claim 49 (depends on 48)

The method of claim 48, wherein the route is intravenous,

### Claim 50 (depends on 46, 47)

The method of claim 46 or 47, wherein the routes of administration are different.

### Claim 51 (depends on 50)

The method of claim 50, wherein the nanobiologic composition is administered intravenously.

### Claim 52 (depends on 43)

The method of claim 43, wherein the trained immunity promoter is a Dectin-1 receptor agonist.

### Claim 53 (depends on 52)

The method of claim 52, wherein the Dectin-1 receptor agonist is an HKCA (heat-killed Candida albicans).

### Claim 54 (depends on 43)

The method of claim 43, wherein the trained immunity promoter is a NOD-2 agonist.

### Claim 55 (depends on 54)

The method of claim 54, wherein the NOD2-agonist is a muramyl dipeptide (MDP) a muramyl tri-peptide (MTP) or a derivative or pro-drug thereof.

### Claim 56 (depends on 54)

The method of claim 54, wherein NOD2-agonist is a muramyl tripeptide phosphatidylethanolamine.
